Stable Aqueous Silicon Complex via pH and Chelate Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing aqueous silicon compositions are limited by the instability and low bioavailability of silicon compounds, particularly in alkaline solutions, which leads to the formation of insoluble oligomeric or polymeric forms, reducing biological activity and making high-concentration, monomeric organosilanol solutions unattainable for industrial-scale production.
Innovation Solution
A stable and highly bioavailable aqueous silicon complex is developed, comprising a monomeric organosilanolate with a pH between 9 and 13, using a chelate with a divalent or trivalent metal cation and an amino acid or aromatic compound, which maintains stability and bioactivity, allowing for high concentrations of silicon in a monomeric form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If alkaline organosiliconate precursors are used to produce aqueous silicon compositions, then the initial stability and solubility are improved, but the compositions condense to form insoluble oligomeric or polymeric forms when stored at pH lower than 13, reducing biological activity
Solution Approach 1:
The patent changes the pH parameter from alkaline (pH > 13) to acidic (pH 2-7) to stabilize the organosilanol solution. This parameter change prevents polycondensation while maintaining monomeric form and biological activity, resolving the contradiction between stability and biological activity
Solution Approach 2:
The patent introduces an intermediary substance (stabilizing agent or complexing agent) that mediates between the organosiliconate precursor and the final organosilanol product. This intermediary prevents direct polycondensation reactions while allowing the solution to be stored at acidic pH, thereby maintaining both stability and biological activity
2Quantity of substance
If the concentration of organosilanol is increased to achieve optimal biological action, then the biological effectiveness is improved, but polycondensation is promoted leading to insoluble forms and reduced bioavailability
Solution Approach 1:
The patent changes the pH parameter to acidic range (pH 2-7), which suppresses polycondensation reactions even at high organosilanol concentrations. This allows achieving optimal biological concentration while maintaining monomeric form stability
Solution Approach 2:
The stabilizing agent acts as an intermediary that complexes with organosilanol molecules, preventing them from undergoing polycondensation even at high concentrations. This enables high concentration formulations while maintaining monomeric stability and bioavailability
3Stability of the object's composition
If very dilute formulations are produced to maintain stability, then the stability is improved, but the production costs increase due to volume constraints and heavy logistics requirements
Solution Approach 1:
The patent changes the pH from alkaline to acidic, which allows concentration of the formulation without triggering polycondensation. This eliminates volume constraints and reduces logistics requirements while maintaining stability, thereby improving ease of manufacture
Solution Approach 2:
The stabilizing agent serves as an intermediary that enables high-concentration formulations by preventing polycondensation. This eliminates the need for very dilute formulations, reducing production volumes and associated logistics costs while maintaining stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable, highly bioavailable silicon complex that maintains monomeric form for therapeutic applications, enhancing biological effects on connective tissues and keratinous tissues, and can be used in various applications without the volume constraints and stability issues of previous methods.
Implementation Method 1
contacting a1) of a metal chelate, a2) of a monomeric organoalkoxysilane, a3) of an aqueous liquid phase, and a4) of a base, thus obtaining an alcoholic aqueous phase whose pH is between 9 and 13 and comprising the silicon complex
Data Source
AI summary
The present invention provides an aqueous composition comprising a silicon complex. The composition comprises (i) a monomeric organosilanolate that comprises 1 to 3 oxygen atoms per silicon atom, said organosilanolate being of formula (R1)nSi(O1-)4-n where n is equal to 1, 2, or 3 and R1 is chosen from alkyl radicals comprising 1 to 4 carbon atoms, phenyl or vinyl groups, and (ii) at least one chelate that comprises at least one chelated metal cation and at least one chelating ligand chosen from amino acids and aromatic compounds substituted in position 1 and 2. The invention also provides a method for preparing the composition and the use of same in different fields.